secwatch.observer — SEC 8-K summary
======================================

Issuer:     Carisma Therapeutics Inc. (CARM)
CIK:        0001485003
Form:       8-K
Filed at:   2023-03-02T23:59:59+00:00
Accession:  0001485003-23-000096
Event type: m_and_a
Sentiment:  positive
Materiality: 0.90
Item codes: 3.03, 5.07, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sesen Bio stockholders approve merger with Carisma; declares $75M special dividend
--------------------------------------------------------------------------------

- Over 88% of votes cast approved the merger with Carisma Therapeutics; merger expected to close March 7, 2023.
- Board declared a one-time special cash dividend of $75M ($0.361 per share) payable by March 10, 2023 to record holders on March 7.
- Reverse stock split of 1-for-20 approved; effective after trading hours on March 7, 2023; post-split shares trade as CARM on March 8.
- Stockholders will receive one Contingent Value Right per share for potential proceeds from Vicineum sale or Roche milestone.
- Sesen Bio expects to close merger with approximately $150M cash; $75M returned to stockholders via dividend.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1485003/000148500323000096/0001485003-23-000096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1485003/000148500323000096/sesn-20230302.htm
  HTML page:      https://secwatch.observer/filing/0001485003-23-000096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer